Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST
In Partnership With:
Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Cogent Biosciences, we had the pleasure of speaking with Robin Jones, MD, MRCP, and Neeta Somaiah, MD, about the phase 3 Peak trial (NCT05208047) in patients with gastrointestinal stromal tumor (GIST). Dr Jones is a consultant medical oncologist, a professor of medical oncology, and the head of the Sarcoma Unit at The Royal Marsden NHS Foundation Trust in London, United Kingdom. Dr Somaiah is an associate professor and the deputy department chair of the Department of Sarcoma Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
The 2-part Peak trial is evaluating the TKI bezuclastinib (CGT9486) plus sunitinib (Sutent) vs sunitinib alone in patients with GIST. The first evaluation of part 1 included patients who had received at least 1 prior line of therapy for GIST. The second evaluation of part 1 included patients who had received at least 2 prior TKIs for GIST. Part 2 of this trial is enrolling patients with disease progression on or intolerance to the TKI imatinib (Gleevec).
In our exclusive interview, Drs Jones and Somaiah discussed unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Cogent Biosciences. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
